Advanced search
Publication Cover
Acta Cardiologica Volume 75, 2020 - Issue 8
Submit an article Journal homepage
181
Views
8
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon – a step forward?

Shibu MathewDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany; Correspondence[email protected]
,
Laura RottnerDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Laura WarnekeDepartment of Cardiology, Asklepios Klinikum Harburg, Hamburg, Germany
,
Tilman MaurerDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Christine LemesDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Naotaka HashiguchiDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Bruno ReißmannDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Britta GoldmannDepartment of Cardiology, Asklepios Klinikum Harburg, Hamburg, Germany
,
Feifan OuyangDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Karl-Heinz KuckDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
,
Andreas MetznerDepartment of Cardiology, Asklepios Klinikum Harburg, Hamburg, Germany
&
Andreas RilligDepartment of Cardiology, Asklepios Klinik St. George, Hamburg, Germany;
show all
Pages 754-759 | Received 18 Jul 2019, Accepted 01 Oct 2019, Published online: 19 Oct 2019

References

  • Metzner A, Reissmann B, Rausch P, et al. One-year clinical outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon. Circ Arrhythm Electrophysiol. 2014;7(2):288–292.
  • Wissner E, Heeger CH, Grahn H, et al. One-year clinical success of a 'no-bonus' freeze protocol using the second-generation 28 mm cryoballoon for pulmonary vein isolation. Europace. 2015;17(8):1236–1240.
  • Metzner A, Heeger CH, Wohlmuth P, et al. Two-year outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon: lessons from the bonus freeze protocol. Clin Res Cardiol. 2015;105(1):72–78.
  • Ciconte G, de Asmundis C, Sieira J, et al. Single 3-minute freeze for second-generation cryoballoon ablation: one-year follow-up after pulmonary vein isolation. Heart Rhythm. 2015;12(4):673–680.
  • Furnkranz A, Bordignon S, Dugo D, et al. Improved 1-year clinical success rate of pulmonary vein isolation with the second-generation cryoballoon in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2014;25(8):840–844.
  • Lemes C, Wissner E, Lin T, et al. One-year clinical outcome after pulmonary vein isolation in persistent atrial fibrillation using the second-generation 28 mm cryoballoon: a retrospective analysis. Europace. 2015;18(2):201–205.
  • Tscholl V, Lsharaf AK, Lin T, et al. Two years outcome in patients with persistent atrial fibrillation after pulmonary vein isolation using the second-generation 28 mm cryoballoon. Heart Rhythm. 2016;13(9):1817–1822.
  • Boveda S, Metzner A, Nguyen DQ, et al. Single-procedure outcomes and quality of life improvement 12 months post-cryoballoon ablation in persistent atrial fibrillation: results from the Multicenter CRYO4PERSISTENT AF TRIAL. JACC Clin Electrophysiol. 2018;4(11):1440–1447.
  • Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation of paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–2245.
  • Heeger CH, Wissner E, Mathew S, et al. Once isolated, always isolated? Incidence and characteristics of pulmonary vein reconduction after second-generation cryoballoon-based pulmonary vein isolation. Circ Arrhythm Electrophysiol. 2015;8(5):1088–1094.
  • Bordignon S, Furnkranz A, Perrotta L, et al. High rate of durable pulmonary vein isolation after second-generation cryoballoon ablation: analysis of repeat procedures. Europace. 2015;17(5):725–731.
  • Reissmann B, Wissner E, Deiss S, et al. First insights into cryoballoon-based pulmonary vein isolation taking the individual time-to-isolation into account. Europace. 2017;19(10):1676–1680.
  • Chun KJ, Stich M, Fürnkranz A, et al. Individualized cryoballoon energy pulmonary vein isolation guided by real time pulmonary vein recordings, the randomized “ICE-T” Trial. Heart Rhythm. 2017;14(4):495–500.
  • Fürnkranz A, Bologna F, Bordignon S, et al. Procedural characteristics of pulmonary vein isolation using the novel third-generation cryoballoon. Europace. 2016;18(12):1795–1800.
  • Chierchia GB, Mugnai G, Ströker E, et al. Incidence of real-time recordings of pulmonary vein potentials using the third-generation short-tip cryoballoon. Europace. 2016;18(8):1158–1163.
  • Koektuerk B, Yorgun H, Koektuerk O, et al. Cryoballoon ablation for pulmonary vein isolation in patients with atrial fibrillation: preliminary results using novel short-tip cryoballoon. J Interv Card Electrophysiol. 2016;47(1):91–98.
  • Heeger CH, Schuette C, Seitelberger V, et al. Time-to-effect guided pulmonary vein isolation utilizing the third-generation versus second generation cryoballoon: one year clinical success. Cardiol J. 2018;26(4):368–374.
  • Fürnkranz A, Bordignon S, Böhmig M, et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm. 2015;12(2):268–274.
  • Metzner A, Burchard A, Wohlmuth P, et al. Increased incidence of esophageal thermal lesions using the second-generation 28-mm cryoballoon. Circ Arrhythm Electrophysiol. 2013;6(4):769–775.
  • Metzner A, Rausch P, Lemes C, et al. The incidence of phrenic nerve injury during pulmonary vein isolation using the second-generation 28 mm cryoballoon. J Cardiovasc Electrophysiol. 2014;25(5):466–470.
  • Casado-Arroyo R, Chierchia GB, Conte G, et al. Phrenic nerve paralysis during cryoballoon ablation for atrial fibrillation: a comparison between the first- and second-generation balloon. Heart Rhythm. 2013;10(9):1318–1324.
  • Straube F, Dorwarth U, Pongratz J, et al. The fourth cryoballoon generation with a shorter tip to facilitate real-time pulmonary vein potential recording: feasibility and safety results. J Cardiovasc Electrophysiol. 2019;30(6):918–925.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.